NGFN-PLUS
PaCaNet TP1 Platform "Clinical Data and Resources"
| Coordinator: | Dr. Nathalia Giese | |
| Institution: | Universitätsklinikum Heidelberg | |
| Homepage: | www.klinikum.uni-heidelberg.de |
TP1 developed an infrastructure, which enabled a standardized collection, processing, validation and distribution of the samples within PaCaNet. The biobank contains 2246 samples obtained from 656 patients: 329 PDAC, 88 IPMT, 25 neuroendocrine, 60 rare, 137 chronic pancreatitis (CP) patients and 6 organ donors. The paraffin-embedded collection is composed of 878 samples: 500 tumor lesions, 203 peritumoral or inflammed areas, 124 CP and 16 peri-CP lesions, and 6 donor pancreata; 8 metastasis/primary tumor pairs and 21 perimetastatic lesions. The samples are also available as fine-needle (n=233) and frozen material (n=840). Biofluids collection contains sera (n=268) and urine (n=27) samples (TP1a). The provision of the standardized resources was enabled through Web-based operation system. This administrative platform was newly developed for PacaNet and is consequently used thereafter (TP1a).
The tissue collection was validated by means of reference pathology (TP1b) and served two goals. 1) More than 3000 biosamples were distributed upon request over the web-based operation system within the NGFN-network (TP1a). The depleted biosamples were replaced with a new material, thereby keeping the collection volume constant. 2) Production of Tissue-microarrays (TMA; TP1b). TMA-Stock currently contains 10 replicas of TMAs for PDAC Grade 1-3, CP and donor pancreata; 25 patients for each entity in triplicate cores. IPMN-TMA contains biopsies from the patients having gastric (n=23) or intestinal (n=7) type of neoplasm. Validated rare forms (PanIN and primary metastatic lesion pairs) are in stock, with TMAs being made on demand.
TP1 also performed validation of ‘Central Track’ Target Genes. The qRT-PCR and Ventana-based immunohistochemical staining & quantification analyses were completed for 6 Central-Track target genes (TP1a and TP1b). In addition, we evaluated ‘second line’ gene CASC5. Upon molecular and functional characterization, CASC5 was considered as suitable candidate considered for 'small molecule inhibitor' screen and for the generation of the conditional transgenic mice.
In order to facilitate development of primary tumor cell-based preclinical models, TP1c generated 43 human tumor xenografts and 119 murine sera (collected in the course of F0-F3 propagation).
Further Coordinators:
The tissue collection was validated by means of reference pathology (TP1b) and served two goals. 1) More than 3000 biosamples were distributed upon request over the web-based operation system within the NGFN-network (TP1a). The depleted biosamples were replaced with a new material, thereby keeping the collection volume constant. 2) Production of Tissue-microarrays (TMA; TP1b). TMA-Stock currently contains 10 replicas of TMAs for PDAC Grade 1-3, CP and donor pancreata; 25 patients for each entity in triplicate cores. IPMN-TMA contains biopsies from the patients having gastric (n=23) or intestinal (n=7) type of neoplasm. Validated rare forms (PanIN and primary metastatic lesion pairs) are in stock, with TMAs being made on demand.
TP1 also performed validation of ‘Central Track’ Target Genes. The qRT-PCR and Ventana-based immunohistochemical staining & quantification analyses were completed for 6 Central-Track target genes (TP1a and TP1b). In addition, we evaluated ‘second line’ gene CASC5. Upon molecular and functional characterization, CASC5 was considered as suitable candidate considered for 'small molecule inhibitor' screen and for the generation of the conditional transgenic mice.
In order to facilitate development of primary tumor cell-based preclinical models, TP1c generated 43 human tumor xenografts and 119 murine sera (collected in the course of F0-F3 propagation).
KTT
MEDIA
CURRENT
NGFN-MEETING-2012
NGFN- MEETING
NGFN1&2
LINKS